-
Study On Cardiovascular Safety of Celebrex Reported at 2005 ACR Meeting
No Increased Risk Of Heart Attack Or Stroke For Patients Taking Celebrex According to a meta-analysis reported by Dr. Lee Simon, Associate Clinical Professor of Medicine at Harvard Medical School, the COX-2 specific…
-
Did GlaxoSmithKline Mislead The FDA As Regards Asthma Drug Serevent?
Consumer Group Public Citizen Allegation In Medical Journal The Lancet In an early October 2005 edition of The Lancet, a British medical journal, a published letter by the American consumer group Public Citizen accused…
-
Serevent, Advair, and Foradil: Increased Risk of Severe Asthma Episodes and Death
FDA MedWatch Alert About LABA Asthma Drugs Follows Health Canada Warning In October 2005 On November 18, 2005 the FDA issued a MedWatch alert regarding Serevent, Advair, and Foradil to inform doctors and patients…
-
“Black-box” Warnings On Drug Labels Often Ignored By Doctors And Patients
Study Indicates Need For Better Presentation of Drug-safety Information On November 18, 2005 the medical journal Pharmacoepidemiology and Drug Safety published findings from a new study which reveals that doctors and patients, both, often…
-
ReoPro Stroke Trial Halted by Lilly and J&J Due To Emerging Safety Issue
Higher Risk of Brain Hemorrhage In Acute Ischemic Stroke Patients Treated With ReoPro On October 28, 2005 Eli Lilly & Co. and Johnson & Johnson’s Centocor unit announced that they had permanently stopped a…
-
Increasing Number of New Drug Trials Are Ended Early Due To Benefits Found
The Downside: Potential Safety Problems May Remain Hidden Until Later The "News roundup" section of the November 12, 2005 edition of the British Medical Journal ("BMJ") included an article by Michael Day about how…
